MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.
MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.